You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Viruses
Download PDF
  • Editorial
  • Open Access

1 February 2022

Broad-Spectrum Antivirals and Antiviral Drug Combinations

and
1
Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway
2
Department for Cancer Research and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7491 Trondheim, Norway
3
Institute of Technology, University of Tartu, 50090 Tartu, Estonia
*
Author to whom correspondence should be addressed.
Viruses2022, 14(2), 301;https://doi.org/10.3390/v14020301
This article belongs to the Special Issue Broad Spectrum Antivirals and Antiviral Combinations
Version Notes
Order Reprints
Viral diseases consistently pose a substantial economic and public health burden worldwide. This burden is due to the viruses’ ability to be transmitted from wild and domestic animals to humans, resulting in unpredictable outbreaks [1]. The current strategy for viral outbreak management is heavily reliant on vaccines and antiviral treatments [2]. While the development of novel vaccines is often long, laborious, and unprofitable, broad-spectrum antivirals (BSAs) remain a timely and effective disease management option, which reduce virus transmission from human to human [3].
BSAs inhibit the replication of multiple viruses from the same or different viral families. To mitigate the development of antiviral drug resistance and increase their efficacy, antivirals are combined into BSA-containing drug cocktails (BCCs) [4,5,6]. Synergistic BCCs have lower concentrations of antivirals, which reduces their toxicity and side effects. There are hundreds of known BSAs and BCCs [4,7].
In this Special Issue, authors report novel, and review known, BSAs and BCCs [8,9,10,11] -. Their results indicate that the landscape of BSAs and BCCs activities and virus coverage is vast, and can be further interrogated and expanded. The basic science data generated by these articles unveil new insights into the interactions between virus and host during viral infections and decipher the mechanisms of action of inhibitors and modulators of these interactions [8,9,10,11,12]. This may help us to uncover critical virus–host interactions and the underlying principles, which determine pan- and cross-family activities of BSAs, as well as understand what makes some BCCs act synergistically, something that is still largely unknown in the medical science community.
Many more BSAs and BCCs are awaiting discovery and development. However, new methods are needed to identify and prioritize the development of a few of the thousands of potential pan- and cross-virus family therapeutic [5,13]. Such methods can assist the global health community by providing new options to fight ongoing and recurrent viral outbreaks. They can also serve as a general paradigm in the quest for proactive global preparedness for future virus outbreaks by providing cost-effective and life-saving countermeasures that can be deployed during the critical period between virus identification and the development of vaccines, virus-specific drugs, and therapeutic antibodies.

Author Contributions

All authors wrote the article. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the European Regional Development Fund, the Mobilitas Pluss Project grant MOBTT39 from Estonian Research Council.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Choi, Y.K. Emerging and re-emerging fatal viral diseases. Exp. Mol. Med. 2021, 53, 711–712. [Google Scholar] [CrossRef] [PubMed]
  2. Monto, A.S. Vaccines and antiviral drugs in pandemic preparedness. Emerg. Infect. Dis. 2006, 12, 55–60. [Google Scholar] [CrossRef] [PubMed]
  3. Ianevski, A.; Andersen, P.I.; Merits, A.; Bjoras, M.; Kainov, D. Expanding the activity spectrum of antiviral agents. Drug Discov. Today 2019, 24, 1224–1228. [Google Scholar] [CrossRef] [PubMed]
  4. Ianevski, A.; Yao, R.; Biza, S.; Zusinaite, E.; Mannik, A.; Kivi, G.; Planken, A.; Kurg, K.; Tombak, E.M.; Ustav, M., Jr.; et al. Identification and Tracking of Antiviral Drug Combinations. Viruses 2020, 12, 1178. [Google Scholar] [CrossRef] [PubMed]
  5. White, J.M.; Schiffer, J.T.; Bender Ignacio, R.A.; Xu, S.; Kainov, D.; Ianevski, A.; Aittokallio, T.; Frieman, M.; Olinger, G.G.; Polyak, S.J. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021, 12, e0334721. [Google Scholar] [CrossRef] [PubMed]
  6. Ahmed, A.; Felmlee, D.J. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015, 7, 6716–6729. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 2020, 93, 268–276. [Google Scholar] [CrossRef] [PubMed]
  8. Ianevski, A.; Yao, R.; Lysvand, H.; Grodeland, G.; Legrand, N.; Oksenych, V.; Zusinaite, E.; Tenson, T.; Bjoras, M.; Kainov, D.E. Nafamostat-Interferon-alpha Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. Viruses 2021, 13, 1768. [Google Scholar] [CrossRef] [PubMed]
  9. Ianevski, A.; Yao, R.; Zusinaite, E.; Lello, L.S.; Wang, S.; Jo, E.; Yang, J.; Ravlo, E.; Wang, W.; Lysvand, H.; et al. Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses 2021, 13, 2489. [Google Scholar] [CrossRef] [PubMed]
  10. Wahaab, A.; Mustafa, B.E.; Hameed, M.; Stevenson, N.J.; Anwar, M.N.; Liu, K.; Wei, J.; Qiu, Y.; Ma, Z. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review. Viruses 2021, 14, 44. [Google Scholar] [CrossRef] [PubMed]
  11. Munshi, S.; Neupane, K.; Ileperuma, S.M.; Halma, M.T.J.; Kelly, J.A.; Halpern, C.F.; Dinman, J.D.; Loerch, S.; Woodside, M.T. Identifying Inhibitors of −1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. Viruses 2022, 14, 177. [Google Scholar] [CrossRef] [PubMed]
  12. Ianevski, A.; Yao, R.; Zusinaite, E.; Lysvand, H.; Oksenych, V.; Tenson, T.; Bjoras, M.; Kainov, D. Active Components of Commonly Prescribed Medicines Affect Influenza A Virus-Host Cell Interaction: A Pilot Study. Viruses 2021, 13, 1537. [Google Scholar] [CrossRef] [PubMed]
  13. Ianevski, A.; Yao, R.; Simonsen, R.M.; Myhre, V.; Ravlo, E.; Kaynova, G.D.; Zusinaite, E.; White, J.M.; Polyak, S.J.; Oksenych, V.; et al. Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness. bioRxiv 2022. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention
Previous
CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
Next